drugset / Trial / NCT02629861

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

NCT02629861

Phase 3 Completed 875 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine

Timeline

Start
2016-03-23
Primary completion
2017-04-10
Completion
2017-04-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fremanezumab Monoclonal antibody 225 mg Subcutaneous
Subject Fremanezumab Monoclonal antibody 675 mg Subcutaneous

Indications